Energenesis Biomedical
Taipei, Taiwan· Est.
Taiwanese biotech advancing small‑molecule topical therapies for diabetic wound healing.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Taiwanese biotech advancing small‑molecule topical therapies for diabetic wound healing.
Diabetic Wound HealingEndocrinology
Technology Platform
Proprietary small‑molecule topical formulation (ENERGI‑F703) that promotes angiogenesis and tissue regeneration for diabetic foot ulcers.
Opportunities
Leveraging FDA‑cleared Phase II data to secure partnerships and expand into broader chronic wound indications.
Risk Factors
Regulatory uncertainty, competition from biologics and tissue‑engineered products, and limited funding for later‑stage trials.
Competitive Landscape
Competes with biologic and tissue‑engineered ulcer therapies; differentiation lies in a small‑molecule, potentially lower‑cost topical approach.